CRL — Charles River Laboratories International, Inc.

Summary of Charles River Laboratories Q4 and Full Year 2025 Earnings Call

1. Key Financial Results and Metrics

• Q4 2025 Revenue: $994.2 million, a 2.6% organic decline year-over-year.
• Full Year 2025 Revenue: $4.02 billion, a 1.6% organic decrease, primarily due to lower revenue in the DSA manufacturing segment.
• Earnings Per Share (EPS): Q4 EPS was $2.39, down 10.2% from $2.66 in Q4 2024; full-year EPS was nearly flat at $10.28 compared to $10.32 in 2024.
• Operating Margin: Q4 margin decreased to 18.1%, a 180 basis point decline; full-year margin was 19.8%, down 10 basis points.
• DSA Revenue: Q4 revenue was $591.6 million, a 3.3% organic decline; full-year DSA revenue decreased 2.6%.
• RMS Revenue: Q4 revenue was $206.3 million, a 0.9% organic decline; full-year RMS revenue increased 1.2%.
• Manufacturing Solutions Revenue: Q4 revenue was $196.4 million, a 2.1% organic decline; full-year revenue declined 1.6%.

2. Strategic Updates and Business Highlights

• Market Trends: Stabilization in biopharma demand was noted, with improved DSA net bookings, particularly in Q4.
• Acquisitions: Completed acquisition of K.F. (Cambodia) to enhance DSA supply chain; acquisition of PathoQuest expected to close soon, aimed at advancing NAMs capabilities.
• Cost-Saving Initiatives: Continued focus on operational efficiency, with expected annualized cost savings exceeding $300 million from restructuring efforts.
• NAMs Development: Emphasis on new approach methodologies (NAMs) and AI integration to enhance drug development processes.

3. Forward Guidance and Outlook

• 2026 Revenue Guidance: Expected organic revenue to range from a decline of 1% to flat, with a potential return to growth in the second half of the year.
• Operating Margin Improvement: Anticipated improvement of 20 to 50 basis points, driven by the K.F. acquisition and cost-saving measures.
• EPS Guidance: Projected non-GAAP EPS between $10.70 and $11.20, representing growth of 4% to 9%.
• Segment Expectations: RMS revenue expected to decline low to mid-single digits; DSA revenue anticipated to be slightly positive to low single-digit decrease; Manufacturing segment expected to rebound with low single-digit growth.

4. Bad News, Challenges, or Points of Concern

• Revenue Declines: All business segments reported revenue declines in Q4, with ongoing challenges in the RMS and DSA segments.
• Higher Costs: Increased NHP sourcing costs and staffing expenses negatively impacted margins, particularly in DSA.
• Market Volatility: Concerns over the sustainability of improved demand trends, particularly given the historical volatility in biotech funding and client spending.
• First Quarter Headwinds: Anticipated challenges in Q1 2026 due to timing of NHP shipments and increased stock compensation expenses related to the CEO transition.

5. Notable Q&A Insights

• NHP Dynamics: Discussion on the contrasting impacts of NHP volumes on RMS and DSA, with RMS facing headwinds from lower volumes while DSA experienced higher sourcing costs due to increased demand.
• Hiring Needs: Management indicated they are in good shape regarding staffing levels to meet anticipated demand, with a focus on direct labor hiring ahead of need.
• AI and NAMs: Management views AI as an enabling technology rather than a disruptor, emphasizing its potential to complement existing processes rather than replace them.
• Cancellations and Slippage: Cancellations were reported to be back to normal levels, with effective management of slippage and backlog ensuring minimal impact on revenue generation.

Overall, while Charles River Laboratories faced challenges in 2025, there are signs of stabilization and potential growth in 2026, supported by strategic acquisitions and a focus on operational efficiencies.